Commonly performed calculations and criteria in CML
This applet is free for your personal use. However please note that use of this applet is for educational purposes only and you use the information provided here at your own risk. You are advised to double check the values obtained here prior to use.
© Dr. Alan Teh 2011
For more apps, visit :
Spleen size (cm)
% Myeloblasts in blood
Sokal JE, Baccarani M, et al. Prognostic discrimination among younger patients with chronic granulocytic leukemia: Relevance to bone marrow transplantation. Blood. 1985; 66: 1352-1367.
Spleen size (cm)
% Myeloblasts in PB
% Eosinophils in PB
% Basophils in PB
The prognostic score was originally developed for patients with chronic myeloid leukemia treated with interferon alfa.
The exclusion criteria were:
(1) > 10% blasts in peripheral blood
(2) blasts + promyelocytes > 30% in peripheral blood
(3) > 15% blasts in bone marrow
(4) blasts + promyelocytes > 50% in bone marrow
(5) extramedullary manifestations
(6) 2 Philadelphia chromosomes, trisomy 8 or isochromosome 17
Hasford J, Pfirrmann M, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Nat Cancer Inst. 1998; 90: 850-858.
Click on a one of the choices above
Vardiman JW, Pierre R, et al. Chronic myelogenous leukemia, pages 20-26. (Table 1.03, page 21; Table 1.04, page 23). IN: Jaffe ES, Harris NL, et al. Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours. IARC Press. 2001
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009 Jul 30;114(5):937-51.
% Basophils PB
The EUTOS score predicts complete cytogenetic remission (CCyR) 18 months after the start of therapy. Patients without CCyR at this point of treatment are less likely to achieve one later on and are at a high risk of progressing to blastic and accelerated phase disease.
The strongest predictors for CCyR at 18 months are spleen size and percentage of basophils. Spleen size is measured in cm under the costal margin, basophils as their percent in peripheral blood. Both need to be assessed at baseline. Their relationship to CCyR is expressed by the formula:
0.0700 * Basophils + 0.0402 * Spleen size
If the sum is greater than 0.8754, the patient is at high risk of not achieving a CCyR at 18 months, while a sum less than or equal to 0.8754 indicates a low risk.
Hasford J et al: Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood online, 2011 May 2
Management of chronic myeloid leukemia (CML): recommendations from the European LeukemiaNet (ELN). Definitions of failure, suboptimal response, warnings and optimal response
Tap to scroll